// App-Quantinova.ai

335 : Title: IACS-010759 is a novel clinical candidate that targets AML cells by inducing a metabolic catastrophe through inhibition of oxidative phosphorylation

Researchers

Presenter

  • Jennifer R. Molina

Principal Investigators

  • Madhavi Bandi

  • Jennifer Bardenhagen

  • Christopher Bristow

  • Christopher Carroll

  • Edward Chang

  • Ningping Feng

  • Jason Gay

  • Mary Geck Do

  • Jennifer Greer

  • Sha Huang

  • Yongying Jiang

  • Marina Konopleva

  • Polina Matre

  • Jing Han

  • Zhijun Kang

  • Gang Liu

  • Timothy McAfoos

  • Pietro Morlacchi

  • Melinda Smith

  • Sonal Gera

  • Jay Theroff

  • Quanyun Xu

  • Juliana Velez

  • Carlo Toniatti

  • Timothy Heffernan

  • Giulio Draetta

  • M. Emilia Di Francesco

  • Philip Jones

  • Joseph R. Marszalek

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Tuberculosis

  • Lymphomas

  • Melanoma

  • Solid malignancies

  • Microphthalmia, syndromic, 9

Biomarkers

  • N/A

Drug/Treatment

  • IACS-010759

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved